Tivic Health Advances TLR5 Immunotherapy Program

Tivic Health Systems ( (TIVC) ) has shared an announcement.

On May 22, 2025, Tivic Health Systems‘ CEO, Jennifer Ernst, presented at the Sidoti Micro Cap Conference, highlighting the company’s recent advancements in their TLR5 immunotherapy program. This program, which has seen over $140 million in investment, includes Phase III trials for acute radiation syndrome and multiple additional indications, positioning Tivic in the competitive immunotherapeutics market. The company has initiated manufacturing validation, which could lead to sales under emergency use authorization, marking significant progress in their strategic growth and market positioning.

Spark’s Take on TIVC Stock

According to Spark, TipRanks’ AI Analyst, TIVC is a Neutral.

The overall stock score of 43 reflects Tivic Health Systems’ current financial difficulties, including declining revenues and negative profitability. However, recent strategic initiatives and corporate events provide some optimism for future growth. The stock’s technical indicators and valuation remain weak, necessitating significant improvements in financial performance and market sentiment to enhance stock attractiveness.

To see Spark’s full report on TIVC stock, click here.

More about Tivic Health Systems

Tivic Health Systems is a diversified immunotherapeutics company focused on developing non-invasive devices and biologic drugs for various medical conditions. The company operates in the immunotherapy market, which is valued at $183 billion, and is involved in both bioelectronic and biologic immunomodulation.

Average Trading Volume: 1,283,146

Technical Sentiment Signal: Hold

Current Market Cap: $3.78M

See more insights into TIVC stock on TipRanks’ Stock Analysis page.